Background: The prognosis of cancer survivors has dramatically improved, but effective strategies for cancer treatment-related cardiovascular disorders (CTRCD) remain to be elucidated in the emerging field of cardio-oncology. In this study, we investigated risk factors for CTRCD in breast cancer patients treated with trastuzumab. Methods and Results: We performed a retrospective analysis of 141 consecutive women who received adjuvant trastuzumab, and underwent baseline (BL) and follow-up (FU) echocardiography at Juntendo University between April 2010 and December 2016. The major concomitant treatment was anthracyclines in 94% and radiotherapy in 53%. During the median treatment period of 11 months, there were 22 (15.6%) cardiology consultations, 3 (2.1%) treatment interruptions with irreversible CTRCD, and no deaths. Left ventricular ejection fraction (LVEF) was decreased from a median 67.5% (BL) to 63.4% (FU; P<0.0001), with reduced LVEF noted in 26.2% at FU<90%BL, in 13.5% at FU

No abstract

信濃 裕美 1) , 渡部 一宏 1) 2) , 中村 清吾 3) , 玉橋 容子 4) , 土屋 雅勇 5) , 木津 純子 2) , 井上 忠夫 1) 1) 聖路加国際病院薬剤部, 2) 共立薬科大学実務薬学講座, 3) 聖路加国際病院乳腺外科, 4) 聖路加国際病院看護部, 5) 帝京大学薬学部